Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Drug Rating Questionnaire

Submitted by administrator -
Abbreviation
DRQ
Description
Participant liking of OROS-MPH/placebo will be assessed with the Drug Rating Questionnaire. This questionnaire is a derivative of the ARCI Benzedrine scales [Martin et al., 1971] to evaluate likeability and potential abuse based on the subjective response of the participant with ADHD. The Drug Rating Questionnaire is a visual analog scale that includes additional questions that assist in disentangling the therapeutic effects of the medication from the euphoria scales - an important confound as recently articulated by Kollins [2003] in children with ADHD. There are no currently psychometrically validated scales available for such purposes in ADHD adults. The Drug Rating Questionnaire has been used successfully in clinical trials of adults with ADHD.
Category
Substance Use
Subcategory
Drugs
Studies Using This Assessment